Replies to post #43434 on Ayala Pharmaceuticals Inc (ADXS)

[jckrdu]

"the LM platform is adxs"

Agree. Likewise, an allogenic solution (off-the-shelf to treat the majority of the masses) using the LM platform to treat/cure cancer (HOT) is really the holy grail, IMO. So...

I'd be surprised if ADXS licenses worldwide rights for HOT in the same way they licensed worldwide rights for NEO. IMO, licensing individual indications for HOT makes more sense, so ADXS doesn't give away everything in a single deal... unless that deal is a buyout of the entire company.

Will be interesting to see how Lombardo and the BOD play it.

[blueyedcatch]

So the fast and Orphan apply to the NEO as well,because the LM is a huge part of the therapy? Why did`nt Adxs announce that the fast track and Orphan applies to the NEO as well?

[mpreorder]

Link?

[mpreorder]

Bill,
I took a look at the FDA release, and if I'm reading the one you're referring to it's talking basically about stem cell therapies for regenerative medicine. Nothing to do with Advaxis. If I'm wrong please provide a link so we may have a look for ourselves. If I'm correct please be more careful with your interpretation of these types of things.